Topic Overviews

• CME Advances in New-Generation Biologics for Rheumatoid Arthritis (RA)
  Physicians - maximum of 1.5 AMA PRA Category 1 credit(s)™
  • Safety Considerations for New Biologics
    Monika Schoels, MD
  • Beyond TNF: The Role of New Biologics in Rheumatoid Arthritis
    Yusuf Yazici, MD
  • Managing Comorbidity in Rheumatoid Arthritis
    Ronald F. van Vollenhoven, MD, PhD
  More...
• CME Rheumatoid Arthritis Disease and Antitumor Necrosis Factor Therapy
  Physicians - maximum of 1.0 AMA PRA Category 1 credit(s)™
  • Tumor Necrosis Factor-Targeted Therapy: Update From EULAR 2008
    Stanley B. Cohen, MD
  • Disease Remission: A Goal for Rheumatoid Arthritis
    Arthur Kavanaugh, MD
  • The Future for Targeted Therapy
    Philip J. Mease, MD

Conference Spotlight

• CME/CE New Options With Biologics for RA: Recent Advances With Novel Therapeutic Agents With Video
  Physicians - maximum of 0.5 AMA PRA Category 1 credit(s)™
  Nurses - 0.5 nursing contact hours (0.25 contact hours are in the area of pharmacology)

Expert Interviews

• Tumor Necrosis Factor Inhibitors vs New Biologics for the Treatment of Inflammatory Joint Diseases: Evidence on Safety and Efficacy -- An Expert Interview With Jonathan Kay, MDJonathan Kay, MD, summarizes the latest updates with tumor necrosis factor inhibitor for the treatment of RA, as illustrated by data from EULAR 2008.
• The ACR-EULAR Collaboration: An Expert Interview With David A. Fox, MDDavid A. Fox, MD, President, ACR, provides expert commentary to Medscape on the new collaborative initiative between the ACR and EULAR.
• New Options With IL-6 Antagonists: Treating the Systemic Manifestation of RA: An Expert Interview With Joel Kremer, MDJoel Kremer, MD, summarizes some of the recent advances with IL-6 for the treatment of RA, as illustrated by data from EULAR 2008.
• The ACR-EULAR Collaboration: An Expert Interview With Ferdinand C. Breedveld, MD, PhDFerdinand C. Breedveld, MD, PhD, President, EULAR, provides expert commentary to Medscape on the new collaborative initiative between the ACR and EULAR.

Video Commentaries

• EULAR 2008 Highlights From Daniel Furst, MD With VideoDaniel Furst, MD, gives his perspectives on key advances presented at EULAR 2008.
• EULAR 2008 Highlights From Ronald F. van Vollenhoven, MD, PhD
  With VideoRonald F. van Vollenhoven, MD, PhD, gives his perspectives on some of the highlights at EULAR 2008.
• EULAR 2008 Highlights From Maxime Dougados, MD With VideoMaxime Dougados, MD, gives his perspectives on key advances presented at EULAR 2008, including the new initiative on the ACR-EULAR collaboration.

Conference News

• CME IL-6 Inhibitor Plus Methotrexate Induce Remission in Rheumatoid Arthritis Refractory to TNF InhibitorsTocilizumab plus methotrexate is significantly better than placebo at improving symptoms of moderate-to-severe rheumatoid arthritis in patients resistant to tumor-necrosis factor-alpha inhibitors.
  Medscape Medical News, June 16, 2008
• Fibromyalgia Diagnosis Often DelayedPatients with symptoms suggestive of fibromyalgia generally wait from 5 months to 1.5 years (depending on the country) to make an appointment with their physician, according to the results of a survey released here to coincide with the European Union League Against Rheumatism Congress (EULAR) 2008.
  Reuters Health, June 16, 2008
• Foot Problems in Arthritis Patients Often NeglectedRheumatologists need to pay more attention to the foot complaints of their rheumatoid arthritis patients, researchers said here at the European Union League Against Rheumatology (EULAR) 2008 Congress.
  Reuters Health, June 16, 2008
• CME Early Sustained RA Remissions Possible Without the Big GunsA significant number of patients with new-onset rheumatoid arthritis can achieve sustained clinical remissions following initial therapy with traditional disease-modifying antirheumatic drugs.
  Medscape Medical News, June 13, 2008
• Milnacipran Shows Promise for FibromyalgiaIn a phase 3 European study, the investigational agent milnacipran displayed activity against multiple symptoms of fibromyalgia.
  Medscape Medical News, June 13, 2008
• On Second Look, Belimumab Shows Activity Against SLEA human monoclonal antibody has been shown to improve or stabilize disease activity in systemic lupus erythematosus.
  Medscape Medical News, June 13, 2008
• Knee Effusion on Ultrasound Predicts Joint Replacement in OsteoarthritisUltrasound effusion can be used as an independent predictor of the need for joint replacement.
  Medscape Medical News, June 13, 2008
• Undiagnosed Low Vitamin D Levels Extremely Common in Rheumatology PatientsNearly three-quarters of patients who present to a rheumatology clinic have a vitamin D deficiency, Irish researchers reported here at the European Union League Against Rheumatism (EULAR) 2008 meeting.
  Reuters Health, June 13, 2008
• MRSA Infections Possibly Linked to TNF InhibitorsResearchers are reporting for the first time a potential association between the occurrence of methicillin-resistant Staphylococcus aureus (MRSA) infections and therapy with tumor necrosis factor (TNF) inhibitors.
  Reuters Health, June 13, 2008